SCHEMBL17407572

SCHEMBL17407572

O=C(Nc1ccc(Br)cc1Cl)c1cc(Br)ccc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ CTDSP1 Q9GZU7 1/20 0.55
▸ MAPT P10636 4/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ CYP1A2 P05177 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ TP53 P04637 2/20 0.54
▸ AURKA O14965 1/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ PDPK1 O15530 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ GMNN O75496 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ EGFR P00533 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ LYN P07948 1/20 0.54
▸ CHRM2 P08172 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16148682 0.93 KCNMA1 (0.66) KMT2AMEN1CTDSP1MAPTMAPK1
SCHEMBL30771730 0.87 TMPRSS4 (0.63) KMT2AMEN1MAPTMAPK1CYP1A2
SCHEMBL331420 0.87 TMPRSS4 (0.63) KMT2AMEN1MAPTMAPK1CYP1A2
SCHEMBL29617506 0.86 KMT2A (0.78) KMT2AMEN1MAPTMAPK1CYP1A2
SCHEMBL8060476 0.86 KMT2A (0.78) KMT2AMEN1MAPTMAPK1CYP1A2
SCHEMBL7943952 0.83 KCNMA1 (0.60) KMT2AMEN1MAPTCYP1A2CYP2C9
SCHEMBL7517172 0.82 PLAU (0.50) MAPTCYP1A2CYP2C9CYP2C19TP53
SCHEMBL11230861 0.81 NPC1 (0.61) KMT2AMEN1MAPTMAPK1CYP1A2
SCHEMBL30451351 0.81 RAB9A (0.73) KMT2AMEN1CTDSP1MAPTMAPK1
SCHEMBL30771727 0.81 KCNMA1 (0.76) KMT2AMEN1MAPTMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066001-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES SILTI AG (CH) 2024-02-29 — — US disclosed
US-20240066001-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES SILTI AG (CH) 2024-02-29 — — US disclosed
EP-3164125-B1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES NAN GLOBAL LLC (US) 2023-09-06 — — EP disclosed
US-20210186918-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES MOLECULE X LLC 2021-06-24 — — US disclosed
US-10849872-B2 Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes NAN Global, LLC (US) 2020-12-01 — — US disclosed
US-20160000745-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES MOLECULE X LLC 2016-01-07 — — US disclosed
US-20160000745-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES MOLECULE X LLC 2016-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186918-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES GPR119, CPT1B, CPT2 KMT2A 1054/4885MEN1 3979/4885CTDSP1 4050/4885
US-20240066001-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES GPR119, CPT1B, CPT2 KMT2A 1054/4885MEN1 3979/4885CTDSP1 4050/4885
US-20160000745-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES GPR119, CPT1B, CPT2 KMT2A 1054/4885MEN1 3979/4885CTDSP1 4050/4885
US-10849872-B2 Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes GPR119, CPT1B, CPT2 KMT2A 1054/4885MEN1 3979/4885CTDSP1 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback